MMAD is primarily utilized in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. It serves as a potent cytotoxic agent, effectively killing cancer cells when delivered directly to the tumor site. This targeted approach minimizes damage to healthy tissues, reducing side effects compared to traditional chemotherapy. MMAD is often linked to monoclonal antibodies that specifically recognize and bind to antigens on cancer cells, ensuring precise delivery. Its application is particularly significant in treating cancers that are difficult to manage with conventional therapies, such as certain types of breast, lung, and hematologic malignancies. Ongoing research continues to explore its potential in expanding the range of treatable cancers and improving therapeutic outcomes.